- Home
- /
- News
- /
- Biotherapeutics
- /
- October 2009
Biotherapeutics News for October 2009
The new biological medicine Ilaris® (canakinumab) has been approved in the EU to treat adults and children as young as four years old with CAPS, a rare life-long auto-inflammatory disease.
30 October, 2009
The U.S. Food and Drug Administration has approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukaemia, a slowly progressing cancer of the blood and bone marrow.
29 October, 2009
New results have shown that the novel biological therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or ‘flares’ in patients with hard-to-treat gout, one of the most painful forms of arthritis.
26 October, 2009
Cancer Research UK scientists at the University of Southampton have developed a potential new antibody treatment that, in the laboratory, shows significantly increased survival from neuroblastoma, a form of childhood cancer that grows from undeveloped tissue of the nervous system.
09 October, 2009
Sanofi-aventis announced recently that it has signed a binding agreement for the acquisition of Fovea Pharmaceuticals SA (‘Fovea‘), a privately held French research and development biopharmaceutical company, focused on ocular diseases.
05 October, 2009